Market Place
Sourcing Support
All News #Library
Biotech
Revolution, Ascendis Seen As Top Buyout Targets In Biopharma
19 Mar 2026 //
BIOSPACE
TransCon hGH Matches Somatropin in InsiGHTS Turner Trial
17 Mar 2026 //
GLOBENEWSWIRE
Ascendis Pharma Joins TD Cowen Health Care Conference
02 Mar 2026 //
GLOBENEWSWIRE
Pooled 3-Year Data Confirms Renal Function Improvement
07 Nov 2025 //
GLOBENEWSWIRE
3-Year Renal Data In Hypoparathyroidism Shared At Kidney Week
03 Nov 2025 //
GLOBENEWSWIRE
Ascendis Pharma Reports Second Quarter 2025 Financial Results
07 Aug 2025 //
GLOBENEWSWIRE
Ascendis Submits U.S. NDA for TransCon CNP for Achondroplasia
31 Mar 2025 //
GLOBENEWSWIRE
YORVIPATH® Now Available in U.S. for Hypoparathyroidism Treatment
19 Dec 2024 //
GLOBENEWSWIRE
New InsiGHTS Trial of TransCon™ hGH Achieves Primary Goal
16 Dec 2024 //
GLOBENEWSWIRE
FDA Accepts Ascendis Pharma’s Application For Growth Hormone Drug
12 Dec 2024 //
GLOBENEWSWIRE
Data For Adults With Hypoparathyroidism Treated With TransCon PTH
30 Sep 2024 //
GLOBENEWSWIRE
Ascendis Pharma Submits BLA For TransCon hGH
30 Sep 2024 //
GLOBENEWSWIRE
Ascendis Pharma`s hormone disorder therapy gets US approval
13 Aug 2024 //
REUTERS
Significant Improvements in RFR for Adults Chronic Hypoparathyroidism
15 May 2024 //
PHARMIWEB
Ascendis Announces FDA Extension For TransCon PTH Hypoparathyroidism Review
14 May 2024 //
GLOBENEWSWIRE
Sustained Renal Function Improvements In Hypoparathyroidism With TransCon PTH
13 May 2024 //
GLOBENEWSWIRE
TransCon PTH Hypoparathyroidism Data At ECE 2024
09 May 2024 //
GLOBENEWSWIRE
UK MHRA Approves YORVIPATH for Hypoparathyroidism
24 Apr 2024 //
GLOBENEWSWIRE
One-Year Data from Ph 3 Trial of TransCon PTH in Adults with Hypoparathyroidism
17 Jun 2023 //
GLOBENEWSWIRE
Ascendis Results from Phase 1/2 of TransCon IL-2 Accepted for Publication
03 Apr 2023 //
PRESS RELEASE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.